NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Myasthenia Gravis, Generalized

Interventions: Ravulizumab

Countries: Poland

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
* Patients willing to participate in the study and signed Informed Consent Form (ICF).
* Vaccination against N. meningitidis

Exclusion Criteria:

* Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
* Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Locations (12)

Bydgoszcz, Poland
Gdansk, Poland
Katowice, Poland
Krakow, Poland
Lodz, Poland
Lublin, Poland
Poznan, Poland
Poznan, Poland
Szczecin, Poland
Szczecin, Poland
Warsaw, Poland
Wroclaw, Poland